A large review of data from over 3,400 patients looked at how the drug pembrolizumab works for those with HER2-negative advanced gastric cancer or gastroesophageal junction cancer. The study compared using pembrolizumab alone, combining it with chemotherapy, and using chemotherapy by itself.
The findings show that patients who received both pembrolizumab and chemotherapy had better response rates and longer overall survival than those who received chemotherapy alone. While the results for the drug used on its own were more limited, the combination treatment showed a clear advantage in clinical outcomes.
Safety was generally manageable across the studies. The most common side effects included a decrease in neutrophil count and hypothyroidism. Because these findings come from a large review of various studies with some inconsistencies in survival benefits, patients should discuss how these results apply to their specific diagnosis with their oncology team.